Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06051409 · ClinicalTrials.gov registry record · Phase 3
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
A Phase 3 study, sponsored by Ascentage Pharma Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
NCT06051409 is a Phase 3 study that is actively recruiting participants, run by Ascentage Pharma Group. The registered enrollment target is 350 participants.
The verdict
NCT06051409, a Phase 3 study, is actively recruiting participants, sponsored by Ascentage Pharma Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
Study Summary
A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined with chemotherapy in subjects with newly-diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
Interventions
- DRUG Olverembatinib
- DRUG Investigator's choice of TKI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06051409
The ClinicalTrials.gov registry entry for NCT06051409 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascentage Pharma Group, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olverembatinib is the first listed.
NCT06051409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06051409 about?
NCT06051409 is a clinical study titled "A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)". A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined with chemotherapy in subjects with newly-diagnosed Philadelphia Chromoso...
What is the current status of trial NCT06051409?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2023-08-31. Estimated completion is 2029-06-30.
What interventions are being tested in trial NCT06051409?
The interventions under investigation include: Olverembatinib (DRUG), Investigator's choice of TKI (DRUG).
Who is sponsoring clinical trial NCT06051409?
This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.